Use of cancer-directed therapy at the end of life among adolescents and young adults.
Jennifer W MackColin CernikLanfang XuCecile A LaurentLauren FisherNancy CannizzaroJulie MunnekeRobert M CooperJoshua R LakinCorey M SchwartzMallory CaspersonAndrea AltschulerLori S WienerLawrence H KushiChun R ChaoHajime UnoPublished in: Journal of the National Cancer Institute (2024)
More than half of adolescents and young adults receive cancer therapy in the last 90 days of life, and use of novel agents such as targeted therapy and immunotherapy is increasing over time. Although some adolescents and young adults may wish to continue cancer therapy while living with advanced disease, efforts are needed to ensure that use of cancer-directed therapy meets preferences of adolescents and young adults approaching death.